CoChat

Heterogeneity and Similarities in GLP-1 Receptor Agonist Cardiovascular Outcomes Trials

Caruso, Irene, Cignarelli, Angelo, Giorgino, Francesco · 2019 · Trends in Endocrinology & Metabolism
Cited by 58

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

The latest recommendations from the American Diabetes Association and the European Association for the Study of Diabetes prioritize the use of drugs with proven cardiovascular (CV) benefit in patients with established CV disease. Especially among the glucagon-like peptide (GLP)-1 receptor agonists (GLP-1RA) class, results of cardiovascular outcomes trials (CVOT) have been heterogeneous. Baseline characteristics of the population, study design, drugs in the control arm, modifications of CV risk factors, including glycemic control, reduction of hypoglycemia, and the GLP-1RA direct effects on CV cells and tissues, were considered. Ultimately, the time of exposure to the GLP-1RA appears to be the factor most prominently explaining trial heterogeneity. Thus, the CV benefit should be regarded as a class effect of GLP-1RA, as largely similar results are seen for drugs sharing a common mechanism of action.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.tem.2019.07.004

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Research works printed but not linked: 30

  1. Holman, 2017, Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes, N. Engl. J. Med., 377, 1228, 10.1056/NEJMoa1612917 · DOI · Paper page
  2. Gerstein, 2019, Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial, Lancet
  3. Husain, 2019, Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes, N. Engl. J. Med., 10.1056/NEJMoa1901118 · DOI · Paper page
  4. Neal, 2017, Canagliflozin and cardiovascular and renal events in type 2 diabetes, N. Engl. J. Med., 377, 644, 10.1056/NEJMoa1611925 · DOI · Paper page
  5. American Diabetes Association, 2019, Standards of medical care in diabetes – 2019, Diabetes Care, 42, S187
  6. Lim, 2018, Glucagon-like peptide-1 receptor agonists and cardiovascular events: class effects versus individual patterns, Trends Endocrinol. Metab., 29, 238, 10.1016/j.tem.2018.01.011 · DOI
  7. Ryder, 2017, Diabetes medications with cardiovascular protection in the wake of EXSCEL: is there a class effect for long-acting GLP-1 receptor agonists?, Br. J. Diabetes, 17, 131, 10.15277/bjd.2017.147 · DOI
  8. Li, 2018, Glucagon-like peptide-1 receptor agonists and cardiovascular risk reduction in type 2 diabetes mellitus: is it a class effect?, Curr. Cardiol. Rep., 20, 113, 10.1007/s11886-018-1051-2 · DOI
  9. Bethel, 2018, Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis, Lancet Diabetes Endocrinol., 6, 105, 10.1016/S2213-8587(17)30412-6 · DOI · Paper page
  10. Gerstein, 2018, Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide, Diabetes Obes. Metab., 20, 42, 10.1111/dom.13028 · DOI · Paper page
  11. Bain, 2018, Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: rationale, design and patient baseline characteristics for the PIONEER 6 trial, Diabetes Obes. Metab., 21, 499, 10.1111/dom.13553 · DOI · Paper page
  12. Svanström, 2018, Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden, Lancet Diabetes Endocrinol., 7, 106, 10.1016/S2213-8587(18)30320-6 · DOI · Paper page
  13. Boyle, 2018, Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review, Clin. Sci., 132, 1699, 10.1042/CS20171299 · DOI · Paper page
  14. Frank, 2013, Population pharmacokinetics of lixisenatide, a once-daily human glucagon-like peptide-1 receptor agonist, in healthy subjects and in patients with type 2 diabetes, J. Pharm. Drug Deliv. Res., 50, 886
  15. Action to Control Cardiovascular Risk in Diabetes Study Group, 2008, Effect of intensive glucose lowering in type 2 diabetes, N. Engl. J. Med., 358, 2545, 10.1056/NEJMoa0802743 · DOI · Paper page
  16. 2008, Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes, N. Engl. J. Med., 358, 2560, 10.1056/NEJMoa0802987 · DOI · Paper page
  17. UK Prospective Diabetes Study Group, 1998, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6 · DOI · Paper page
  18. Giorgino, 2016, Glucose control and vascular outcomes in type 2 diabetes: is the picture clear?, Diabetes Care, 39, S187, 10.2337/dcS15-3023 · DOI · Paper page
  19. Dalsgaard, 2018, Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: a narrative review of head-to-head comparisons, Diabetes Obes. Metab., 20, 508, 10.1111/dom.13128 · DOI · Paper page
  20. Taylor, 2018, GLP-1 receptor agonists: differentiation within the class, Lancet Diabetes Endocrinol., 6, 83, 10.1016/S2213-8587(17)30413-8 · DOI
  21. Zinman, 2018, Hypoglycemia, cardiovascular outcomes, and death: the LEADER experience, Diabetes Care, 41, 1783, 10.2337/dc17-2677 · DOI · Paper page
  22. Gentilella, 2019, Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?, Diabetes Metab. Res. Rev., 35, 10.1002/dmrr.3070 · DOI · Paper page
  23. Fineman, 2012, Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment, Diabetes Obes. Metab., 14, 546, 10.1111/j.1463-1326.2012.01561.x · DOI · Paper page
  24. Sfairopoulos, 2018, Clinical pharmacology of glucagon-like peptide-1 receptor agonists, Hormones, 17, 333, 10.1007/s42000-018-0038-0 · DOI
  25. Wootten, 2016, The extracellular surface of the GLP-1 receptor is a molecular trigger for biased agonism, Cell, 165, 1632, 10.1016/j.cell.2016.05.023 · DOI · Paper page
  26. Drucker, 2018, The ascending GLP-1 road from clinical safety to reduction of cardiovascular complications, Diabetes, 67, 1710, 10.2337/dbi18-0008 · DOI · Paper page
  27. Leonardini, 2017, GLP-1 receptor activation inhibits palmitate-induced apoptosis via ceramide in human cardiac progenitor cells, J. Clin. Endocrinol. Metab., 102, 4136, 10.1210/jc.2017-00970 · DOI · Paper page
  28. Laviola, 2012, Glucagon-like peptide-1 counteracts oxidative stress-dependent apoptosis of human cardiac progenitor cells by inhibiting the activation of the c-Jun N-terminal protein kinase signaling pathway, Endocrinology, 153, 5770, 10.1210/en.2012-1461 · DOI · Paper page
  29. Al Batran, 2018, Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism, Peptides, 100, 94, 10.1016/j.peptides.2017.12.005 · DOI
  30. Bruen, 2017, Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis, Cardiovasc. Diabetol., 16, 153, 10.1186/s12933-017-0626-3 · DOI · Paper page

Cited by

Metadata

Authors
Caruso, I., Cignarelli, A., & Giorgino, F.
Venue
Trends in Endocrinology & Metabolism
Publisher
Elsevier BV
Published
2019-09
Volume
30
Issue
9
Pages
578-589
ISSN
1043-2760 (ISSN-L)
OpenAlex
W2964603908
Cited by
58
References
31
FWCI
1.95
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.